Clinical Trial Update: A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating induction with alemtuzumab (Campath-1H) in combination with mycophenolate mofetil (CellCept) to enable a calcineurin inhibitor–fr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Campath-1H (alemtuzumab)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Renal Transplantation | Phase 2 | Status: COMPLETED